Drug Type Small molecule drug |
Synonyms Upadacitinib Hydrate, Upadacitinib tartrate, 乌帕奴单抗 + [8] |
Target |
Action inhibitors |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (16 Aug 2019), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Special Review Project (China) |
Molecular FormulaC34H40F6N12O3 |
InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N |
CAS Registry2050057-56-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10994D11048 | Upadacitinib hemihydrate |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Alopecia Areata | European Union | 29 Jul 2026 | |
| Alopecia Areata | Iceland | 29 Jul 2026 | |
| Alopecia Areata | Liechtenstein | 29 Jul 2026 | |
| Alopecia Areata | Norway | 29 Jul 2026 | |
| Nonsegmental vitiligo | European Union | 29 Jun 2026 | |
| Nonsegmental vitiligo | Iceland | 29 Jun 2026 | |
| Nonsegmental vitiligo | Liechtenstein | 29 Jun 2026 | |
| Nonsegmental vitiligo | Norway | 29 Jun 2026 | |
| Giant Cell Arteritis | European Union | 08 Apr 2025 | |
| Giant Cell Arteritis | Iceland | 08 Apr 2025 | |
| Giant Cell Arteritis | Liechtenstein | 08 Apr 2025 | |
| Giant Cell Arteritis | Norway | 08 Apr 2025 | |
| Polyarticular Juvenile Idiopathic Arthritis | United States | 26 Apr 2024 | |
| Crohn's disease, active moderate | European Union | 24 Apr 2023 | |
| Crohn's disease, active moderate | Iceland | 24 Apr 2023 | |
| Crohn's disease, active moderate | Liechtenstein | 24 Apr 2023 | |
| Crohn's disease, active moderate | Norway | 24 Apr 2023 | |
| Crohn's disease, active severe | European Union | 24 Apr 2023 | |
| Crohn's disease, active severe | Iceland | 24 Apr 2023 | |
| Crohn's disease, active severe | Liechtenstein | 24 Apr 2023 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Scleroderma, Systemic | Phase 3 | - | 11 Dec 2026 | |
| Pediatric Crohn's Disease | Phase 3 | United States | 08 Aug 2024 | |
| Pediatric Crohn's Disease | Phase 3 | China | 08 Aug 2024 | |
| Pediatric Crohn's Disease | Phase 3 | Japan | 08 Aug 2024 | |
| Pediatric Crohn's Disease | Phase 3 | Australia | 08 Aug 2024 | |
| Pediatric Crohn's Disease | Phase 3 | Belgium | 08 Aug 2024 | |
| Pediatric Crohn's Disease | Phase 3 | Brazil | 08 Aug 2024 | |
| Pediatric Crohn's Disease | Phase 3 | Bulgaria | 08 Aug 2024 | |
| Pediatric Crohn's Disease | Phase 3 | Canada | 08 Aug 2024 | |
| Pediatric Crohn's Disease | Phase 3 | France | 08 Aug 2024 |
Phase 3 | 385 | moqduafwwg(qqxitoqtpi) = slladzqfun imnfadydzy (sutxppdkgf ) | Positive | 31 Dec 2026 | |||
moqduafwwg(qqxitoqtpi) = nephyjmkca imnfadydzy (sutxppdkgf ) | |||||||
Not Applicable | 75 | tukytbfekm(bkktepdkbq) = miovgbgyjv hvkvwbpnju (wblbbzghtg ) View more | Positive | 06 Nov 2026 | |||
xpctccmsvo(wbricadjhd) = wwbjlswnzi hbkujzyskk (qpqyazzjjx ) | |||||||
Not Applicable | 43 | yqichghjxa(qavhrhaizm) = dxarcahxze nbthdnmkvg (zepbawzuhu ) View more | Positive | 06 Nov 2026 | |||
Not Applicable | 1,797 | aouyzgghoc(tqvzttuaxo) = nyipdeupbo zarijbhjwy (gjbxzfaowl, -1.50 to -0.85) View more | Positive | 06 Nov 2026 | |||
Interleukin-17 inhibitor (IL-17i) | aouyzgghoc(tqvzttuaxo) = sjzujzfvdo zarijbhjwy (gjbxzfaowl, -1.02 to -0.6) View more | ||||||
Not Applicable | 63 | yxzuonvdvb(sbmfhxgvgv) = tkozpebpht fsfihvvpfn (ytooaytbmc ) View more | Positive | 06 Nov 2026 | |||
Phase 1 | 122 | (Prior exposure to csDMARDs) | zgapglrcea(elwmxuiugk) = ylimctgtrd jqlhphyrey (axzphfuqsp ) | Positive | 06 Nov 2026 | ||
(bDMARD-naive) | bdmrlchzit(gufwrzypwx) = mhxappsard fclcrcackl (xbtlghpczw ) View more | ||||||
Phase 3 | 101 | kekjxzuuyy(isfzmxgkdq) = The increase in mean (SD) levels of CRP from period 2 entry to the first flare was 0.7 (2.6) mg/dL for the UPA15/UPA15 group and 2.2 (2.2) mg/dL for the UPA15/PBO group. bstgmpnwsc (ssokcliopr ) View more | Positive | 06 Nov 2026 | |||
Placebo | |||||||
Not Applicable | 1 | kvfzpqmteu(mzvucmbuur) = dpbtrgwcep ettdjgrftp (bvascodkpt ) View more | Positive | 06 Nov 2026 | |||
Not Applicable | 39,603 | iwcorqkdui(kmcksgpssm): HR = 0.84 (95.0% CI, 0.4 - 1.74) View more | Positive | 06 Nov 2026 | |||
Not Applicable | 40 | rjxoksybrr(lhsuujwdoc) = vfjxtghlgg ocsmvuilln (adnivnymdl ) View more | Positive | 06 Nov 2026 |





